Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals. Financial performance shows improvement in losses and revenue growth in key areas, but there are ongoing financial challenges, competitive pressures in the CGM market, and operational risks due to restructuring. The lack of a clear shareholder return plan and unclear management responses in the Q&A add uncertainty. Despite positive revenue growth in TrinScreen HIV and cost reduction efforts, the net loss and financial risks limit optimism, resulting in a neutral stock price prediction.
Key Financial Performance
Revenue $15.2 million, a 3% increase year-over-year, driven by TrinScreen HIV revenues.
TrinScreen Revenue $2.4 million, a 60% increase year-over-year, contributing to overall revenue growth.
Clinical Laboratory Revenue $10.8 million, a 9% decrease year-over-year, primarily due to a 70% decrease in hemoglobin business revenues.
Operating Loss $2.6 million, improved from $4.5 million in Q3 2023, a 42% improvement due to cost reduction initiatives.
Net Loss $4.8 million, improved from $6.7 million in Q3 2023, reflecting better operational performance.
Adjusted EBITDASO $1.4 million loss, improved from $3.5 million loss in Q3 2023, indicating progress in cost management.
Cash Balance $2.8 million at the end of September, down from $5.3 million at June 30, reflecting cash used in operations of $3.6 million.
Cash Used in Operations $3.6 million, an improvement of $1 million compared to Q3 2023.
Cash Inflow from Financing Activities $4.2 million, resulting from an aftermarket offering agreement.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Continuous Glucose Monitor (CGM): Trinity Biotech is progressing towards the commercial launch of its next-generation CGM for diabetes management, targeting a market worth over $10 billion annually.
Prostate Cancer Test Technology: The company has acquired innovative prostate cancer test technology to enhance its product pipeline.
Preeclampsia Test Technology: Trinity Biotech has also acquired preeclampsia test technology to further expand its product offerings.
Sepsis Diagnostic Technology: A strategic investment has been made in a sepsis diagnostic technology to bolster the company's growth potential.
TrinScreen HIV Sales: TrinScreen HIV revenues are projected to reach approximately $10 million in 2024, with expectations of higher revenues in Q4 2024.
Clinical Laboratory Revenues: Clinical laboratory revenues decreased by 9% compared to Q3 2023, but the clinical chemistry portfolio grew by almost 80% year-on-year.
Cost Reduction Initiatives: The company has made significant progress in cost reduction initiatives, with an operating loss improvement from $4.5 million in Q3 2023 to $2.6 million in Q3 2024.
Manufacturing Consolidation: Trinity Biotech is consolidating manufacturing operations, with plans to offshore production to enhance gross margins and working capital.
Transformation Plan: The comprehensive transformation plan is on track, with expectations of achieving approximately $20 million in annualized run rate EBITDASO by Q2 2025.
NASDAQ Compliance: The company has regained compliance with NASDAQ listing requirements, removing an overhang on its stock.
Strategic Partnerships: Trinity Biotech is establishing strategic manufacturing and supply chain relationships to prepare for global scaling upon product launch.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: Recent changes by the U.S. FDA regarding the introduction of new lab-developed tests (LDTs) may limit the ability of non-New York State Department of Health certified laboratories to bring new tests to market, potentially impacting competitive positioning.
Supply Chain Challenges: The company is undergoing a transformation plan that includes consolidating manufacturing and offshoring certain operations, which may pose risks related to execution and operational efficiency during the transition.
Economic Factors: The company operates in a highly regulated environment, which can lead to delays and increased costs associated with compliance and operational changes.
Competitive Pressures: The continuous glucose monitor (CGM) market is highly competitive, and the company must successfully differentiate its product to capture market share in a rapidly growing sector.
Financial Performance Risks: The company has reported operating losses and is in the process of restructuring, which may affect its financial stability and ability to achieve projected revenue and profitability targets.
Market Demand Variability: The company has experienced fluctuations in revenue due to varying ordering patterns from customers, particularly in the HIV rapid test market, which may impact future revenue projections.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Continuous Glucose Monitor (CGM): Planning for long-term growth driven by the commercial launch of a next-generation CGM for diabetes management, targeting a market worth over $10 billion.
Acquisitions: Building a pipeline of high-growth products through acquisitions, including prostate cancer and preeclampsia test technologies, and a strategic investment in sepsis diagnostics.
Transformation Plan: Executing a comprehensive transformation plan to establish profitability infrastructure and enhance existing business lines.
NASDAQ Compliance: Successfully addressing NASDAQ listing deficiencies, removing an overhang from the stock.
TrinScreen HIV Revenue Guidance: Reiterating guidance for 2024 sales revenue of approximately $10 million for TrinScreen HIV.
Q4 Revenue Expectations: Expecting higher revenues in Q4 2024 for TrinScreen HIV, estimating around $3 million.
EBITDASO Guidance: Guidance to achieve approximately $20 million of annualized run rate EBITDASO by Q2 2025.
Revenue Guidance: Targeting annualized run rate revenues of approximately $75 million by Q2 2025.
Cost Reduction Timeline: Expecting significant cost reduction initiatives to be completed by the end of Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
TrinScreen Sales Guidance: The company reiterated its guidance for TrinScreen sales of approximately $10 million for the full year 2024.
Cash Flow from Financing Activities: During the quarter, the company entered into an aftermarket offering agreement, resulting in a positive net cash flow of $7.1 million.
Restructuring Costs: The company incurred restructuring costs of approximately $300,000 related to the comprehensive transformation plan.
Annualized Run Rate Guidance: The company reiterated guidance to achieve approximately $20 million of annualized run rate earnings before interest tax depreciation and share options cost (EBITDASO) and annualized run rate revenues of approximately $75 million by Q2 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Regarding the third quarter, you said you still expect the TrinScreen sales around $10 million. So it sounds like you're looking for a little over $3 million of revenue from that in the Q4. Does that sound right?
A:Yes, we would expect about $3 million for Q4.
Q:With regard to the Premier Instruments, it sounds like those sales were a little lower this quarter as some customers waited for the new column to come out. Do you think that business comes back in the Q4 or do you think that business is lost or do you think it comes back in 2025?
A:I think the core revenue for consumables is broadly consistent quarter-on-quarter. The variation was more due to high variation in ordering patterns across one customer. We expect a temporary reduction in instrument placement revenues.
Q:Did I hear you say you think that these first phase of initiatives they should be complete by the end of Q1 of 2025?
A:Yes, we expect most of these changes to be affected by the end of Q4 this year or very early in 2025.
Q:What's the timeline for the two tuck-in deals you did, the PSA test, the preeclampsia test?
A:We expect the preeclampsia test to be revenue generating in the second half of 2025 and the prostate cancer test in 2026.
Q:What do you expect the share count to be in the Q4 as a result of these two acquisitions?
A:I don't have that number right now. We can go back to you on that.
Q:What are the biggest maybe two or three items that will get you there in the next few quarters?
A:The biggest contributors will be reducing down from three manufacturing sites to one and offshoring some operations.
Q:Are most of the revenues for next year on TrinScreen expected to be from new tenders or building on the existing tender from this current year?
A:A mix. We expect to win additional tenders and evaluations for 2025, but the timing is uncertain.
Q:How much capacity is remaining on the ATM?
A:I think there's about less than a million on the current ATM filing.
Q:Review of Unclear Management Responses
A:Management did not provide a specific answer regarding the expected share count in Q4 as a result of the two acquisitions, stating they would follow up later.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Diagnostics
FDA
HIV test
Metabolomics
New York
Novus
York State
agility
change
column
design
diagnosis
disease
epiCaPture
generation solution
item
journey
lab test
laboratory
manufacturing activity
patient
placement
plant
preeclampsia test
prostate cancer
regard
revenue TrinScreen
sepsis
step
stock
supply chain
tender
test market
testing service
timeline
transfer
transformation plan
treatment
value proposition
variation
TRIB Transcript
Trinity Biotech Plc (TRIB) Q3 2024 Earnings Call Transcript
Unknown11-15
The earnings call reveals mixed signals. Financial performance shows improvement in losses and revenue growth in key areas, but there are ongoing financial challenges, competitive pressures in the CGM market, and operational risks due to restructuring. The lack of a clear shareholder return plan and unclear management responses in the Q&A add uncertainty. Despite positive revenue growth in TrinScreen HIV and cost reduction efforts, the net loss and financial risks limit optimism, resulting in a neutral stock price prediction.
Trinity Biotech plc (TRIB) Q2 2024 Earnings Call Transcript
Unknown8-16
The earnings call summary presents a mixed outlook: strong growth in point-of-care revenues and improved financial health, but challenges like restructuring costs, competitive pressures, and lack of shareholder returns. The Q&A section suggests some uncertainties, particularly with the CGM trials and new Premier instruments. Despite positive elements, such as potential growth in clinical chemistry and a new distribution partner, the absence of clear guidance and shareholder return plans tempers optimism, resulting in a neutral sentiment.
Trinity Biotech plc (TRIB) Q1 2024 Earnings Call Transcript
Unknown5-23
The earnings call presents a mixed picture. While there are improvements in operating and net losses, and revenue growth in the Point-of-Care business, the company faces challenges such as declining clinical laboratory revenues and high debt levels. The Q&A reveals management's reluctance to provide specific details, which may concern investors. Overall, the financial performance and business updates are balanced, leading to a neutral sentiment.
Trinity Biotech plc (TRIB) Q4 2023 Earnings Call Transcript
Positive4-4
The earnings call highlights strong financial management, with reduced financial expenses and a gain from discontinued operations. The Q&A session reveals positive developments like the approval of new diabetes products and plans for market expansion in Africa. While there are some uncertainties, such as the timeline for CGM revenue, the overall sentiment is optimistic with expected revenue growth, cost-saving initiatives, and strategic market positioning. These factors suggest a positive stock price movement.
TRIB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
